{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:20:17Z","timestamp":1777422017118,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018270","name":"Health Service Executive","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001636","name":"University College Cork","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001636","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40266-023-01020-w","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:02:58Z","timestamp":1680166978000},"page":"461-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychotropic Medication Prescribing to Patients with Dementia Admitted to Acute Hospitals in Ireland"],"prefix":"10.1007","volume":"40","author":[{"given":"Suzanne","family":"Timmons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairead","family":"Bracken-Scally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vida","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emer","family":"Begley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-0471","authenticated-orcid":false,"given":"Emma","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3389\/fpsyt.2021.741059","volume":"12","author":"CY Kwon","year":"2021","unstructured":"Kwon CY, Lee B. Prevalence of behavioral and psychological symptoms of dementia in community-dwelling dementia patients: a systematic review. Front Psychiatry. 2021;12:1809.","journal-title":"Front Psychiatry."},{"key":"1020_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1590\/0101-60830000000127","volume":"44","author":"SS Huang","year":"2017","unstructured":"Huang SS, Wang WF, Liao YC. Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan. Arch Clin Psychiatry (S\u00e3o Paulo). 2017;44:89\u201393.","journal-title":"Arch Clin Psychiatry (S\u00e3o Paulo)."},{"key":"1020_CR4","volume-title":"Psychotropic drugs","author":"NL Keltner","year":"1993","unstructured":"Keltner NL, Folks DG. Psychotropic drugs. Maryland: Mosby; 1993."},{"key":"1020_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiat. 2015;72:438\u201345.","journal-title":"JAMA Psychiat"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/qjmed\/hcw114","volume":"110","author":"R Briggs","year":"2017","unstructured":"Briggs R, Dyer A, Nabeel S, Collins R, Doherty J, Coughlan T, et al. Dementia in the acute hospital: the prevalence and clinical outcomes of acutely unwell patients with dementia. QJM. 2017;110:33\u20137.","journal-title":"QJM"},{"key":"1020_CR7","first-page":"17","volume":"64","author":"LM Bjerre","year":"2018","unstructured":"Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64:17\u201327.","journal-title":"Can Fam Physician"},{"key":"1020_CR8","doi-asserted-by":"publisher","first-page":"k2438","DOI":"10.1136\/bmj.k2438","volume":"361","author":"J Pink","year":"2018","unstructured":"Pink J, O\u2019Brien J, Robinson L, Longson D. Dementia: assessment, management and support: summary of updated NICE guidance. BMJ. 2018;361:k2438.","journal-title":"BMJ"},{"key":"1020_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcpt.12357","volume":"41","author":"N El-Saifi","year":"2016","unstructured":"El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016;41:7\u201318.","journal-title":"J Clin Pharm Ther"},{"key":"1020_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1533317511402051","volume":"26","author":"G Henry","year":"2011","unstructured":"Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen\u00ae. 2011;26:169\u201383.","journal-title":"Am J Alzheimers Dis Other Demen\u00ae."},{"key":"1020_CR11","volume-title":"The use of antipsychotic medication for people with dementia: time for action","author":"S Banerjee","year":"2009","unstructured":"Banerjee S. The use of antipsychotic medication for people with dementia: time for action. London: Department of Health; 2009."},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/jgs.17623","volume":"70","author":"A N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard A, Jensen-Dahm C, Wimberley T, Svendsen JH, Ishtiak-Ahmed K, Laursen TM, et al. Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities. J Am Geriatr Soc. 2022;70:1169\u201379.","journal-title":"J Am Geriatr Soc"},{"key":"1020_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7:229\u201345.","journal-title":"Ther Adv Chronic Dis."},{"key":"1020_CR14","volume-title":"Deaths with antipsychotics in elderly patients with behavioral disturbances","author":"US Food and Drug Administration","year":"2005","unstructured":"US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. Washington: Public Health Advisory. US Department of Health and Human Services; 2005."},{"key":"1020_CR15","first-page":"8","volume":"64","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;64:8\u201313.","journal-title":"J Clin Psychiatry"},{"key":"1020_CR16","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934\u201343.","journal-title":"JAMA"},{"key":"1020_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jamda.2016.09.019","volume":"18","author":"L Saarelainen","year":"2017","unstructured":"Saarelainen L, Tolppanen AM, Koponen M, Tanskanen A, Sund R, Tiihonen J, et al. Risk of hip fracture in benzodiazepine users with and without Alzheimer disease. J Am Med Dir Assoc. 2017;18:87-e15.","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"1020_CR18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.euroneuro.2015.08.014","volume":"25","author":"P Jennum","year":"2015","unstructured":"Jennum P, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol. 2015;25(11):1906\u201313.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1020_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000280437","volume":"29","author":"RB Wetzels","year":"2010","unstructured":"Wetzels RB, Zuidema SU, de Jonghe JFM, Verhey FRJ, Koopmans RTCM. Determinants of quality of life in nursing home residents with dementia. Dement Geriatr Cogn Disord. 2010;29:189\u201397.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1020_CR20","volume-title":"Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia","author":"Department of Health","year":"2019","unstructured":"Department of Health. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia. Dublin: Department of Health; 2019."},{"key":"1020_CR21","unstructured":"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. 20 June 2018. www.nice.org.uk\/guidance\/ng97. Accessed 25 Aug 2022."},{"key":"1020_CR22","volume-title":"Clinical practice guidelines and principles of care for people with dementia","author":"National Health and Medical Research Council","year":"2016","unstructured":"National Health and Medical Research Council. Clinical practice guidelines and principles of care for people with dementia. Sydney: Guideline Adaptation Committee; 2016."},{"issue":"5","key":"1020_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","volume":"173","author":"VI Reus","year":"2016","unstructured":"Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543\u20136.","journal-title":"Am J Psychiatry"},{"key":"1020_CR24","unstructured":"Royal College of Psychiatrists. Report of the National Audit of Dementia Care in General Hospitals. Editors: Young J, Hood C, Woolley R, Gandesha A, Souza R. London: Healthcare Quality Improvement Partnership. 2011."},{"key":"1020_CR25","volume-title":"Second Irish National Audit of Dementia Care in Acute Hospitals","author":"M Scally","year":"2020","unstructured":"Scally M, Timmons S, O\u2019Shea E, Gallagher P, Kennelly SP, Hamilton V, O\u2019Neill D. Second Irish National Audit of Dementia Care in Acute Hospitals. Offaly: National Dementia Office; 2020."},{"key":"1020_CR26","volume-title":"Irish National Audit of Dementia Care in Acute Hospitals","author":"A de Si\u00fan","year":"2014","unstructured":"de Si\u00fan A, O\u2019Shea E, Timmons S, McArdle D, Gibbons P, O\u2019Neill D, et al. Irish National Audit of Dementia Care in Acute Hospitals. Cork: National Audit of Dementia Care; 2014."},{"key":"1020_CR27","unstructured":"Department of Health. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia (NCEC National Clinical Guideline No. 21). 2019. https:\/\/www.gov.ie\/en\/collection\/c9fa9a-national-clinical-guidelines\/. Accessed 25 Aug 2022."},{"key":"1020_CR28","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1017\/S1041610216001307","volume":"28","author":"KA Walsh","year":"2016","unstructured":"Walsh KA, O\u2019Regan NA, Byrne S, Browne J, Meagher DJ, Timmons S. Patterns of psychotropic prescribing and polypharmacy in older hospitalized patients in Ireland: the influence of dementia on prescribing. Int Psychogeriatr. 2016;28:1807\u201320.","journal-title":"Int Psychogeriatr"},{"key":"1020_CR29","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1017\/S1041610216001150","volume":"28","author":"SIM Janus","year":"2016","unstructured":"Janus SIM, van Manen JG, Ijzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;28:1775\u201390.","journal-title":"Int Psychogeriatr"},{"key":"1020_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009882","volume":"6","author":"A Szczepura","year":"2016","unstructured":"Szczepura A, Wild D, Khan AJ, Owen DW, Palmer T, Muhammad T, et al. Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions over a 4-year period. BMJ Open. 2016;6: e009882.","journal-title":"BMJ Open"},{"issue":"9","key":"1020_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5694\/mja17.00857","volume":"208","author":"JL Westbury","year":"2018","unstructured":"Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398\u2013403.","journal-title":"Med J Aust"},{"key":"1020_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/S1041610213002019","volume":"26","author":"BC Kleijer","year":"2014","unstructured":"Kleijer BC, van Marum RJ, Frijters DHM, Jansen PAF, Ribbe MW, Egberts ACG, et al. Variability between nursing homes in prevalence of antipsychotic use in patients with dementia. Int Psychogeriatr. 2014;26:363\u201371.","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"1020_CR33","doi-asserted-by":"publisher","first-page":"897.e1","DOI":"10.1016\/j.jamda.2017.06.032","volume":"18","author":"KA Walsh","year":"2017","unstructured":"Walsh KA, Dennehy R, Sinnott C, Browne J, Byrne S, McSharry J, Coughlan E, Timmons S. Influences on decision-making regarding antipsychotic prescribing in nursing home residents with dementia: a systematic review and synthesis of qualitative evidence. J Am Med Dir Assoc. 2017;18(10):897.e1-897.e12. https:\/\/doi.org\/10.1016\/j.jamda.2017.06.032.","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"1020_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jamda.2018.07.004","volume":"19","author":"KA Walsh","year":"2018","unstructured":"Walsh KA, Sinnott C, Fleming A, Mc Sharry J, Byrne S, Browne J, Timmons S. Exploring antipsychotic prescribing behaviors for nursing home residents with dementia: a qualitative study. J Am Med Dir Assoc. 2018;19(11):948-958.e12. https:\/\/doi.org\/10.1016\/j.jamda.2018.07.004.","journal-title":"J Am Med Dir Assoc"},{"key":"1020_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/qjmed\/hcw023","volume":"109","author":"P Gallagher","year":"2016","unstructured":"Gallagher P, Curtin D, De Si\u00fan A, O\u2019Shea E, Kennelly S, O\u2019Neill D, et al. Antipsychotic prescription amongst hospitalized patients with dementia. QJM. 2016;109:589\u201393.","journal-title":"QJM"},{"issue":"2","key":"1020_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jama.2017.7032","volume":"318","author":"JH Gurwitz","year":"2017","unstructured":"Gurwitz JH, Bonner A, Berwick DM. Reducing excessive use of antipsychotic agents in nursing homes. JAMA. 2017;318(2):118\u20139.","journal-title":"JAMA"},{"key":"1020_CR37","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S2468-2667(17)30031-2","volume":"2","author":"K Donegan","year":"2017","unstructured":"Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2:e149\u201356.","journal-title":"Lancet Public Health."},{"issue":"6","key":"1020_CR38","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/13607863.2021.1922601","volume":"26","author":"DA Wiggin","year":"2022","unstructured":"Wiggin DA, Timmons S, Rukundo A, Walsh KA. Improving the appropriateness of psychotropic prescribing for nursing home residents with dementia: an overview of reviews. Aging Ment Health. 2022;26(6):1087\u201394. https:\/\/doi.org\/10.1080\/13607863.2021.1922601.","journal-title":"Aging Ment Health"},{"issue":"5","key":"1020_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ageing\/afy086","volume":"47","author":"K Dalton","year":"2018","unstructured":"Dalton K, O\u2019Brien G, O\u2019Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing. 2018;47(5):670\u20138. https:\/\/doi.org\/10.1093\/ageing\/afy086.","journal-title":"Age Ageing"},{"key":"1020_CR40","unstructured":"Health Service Executive. Guidance on appropriate prescribing of benzodiazepines and z-drugs (BZRA) for the treatment of anxiety and insomnia. Dublin: Health Service Executive. 2021. https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/ncps\/medicines-management\/. Accessed 25 Aug 2022."},{"key":"1020_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/ageing\/afx098","volume":"47","author":"C Mueller","year":"2018","unstructured":"Mueller C, Perera G, Hayes RD, Shetty H, Stewart R. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer\u2019s disease: a retrospective survival analysis. Age Ageing. 2018;47:88\u201394.","journal-title":"Age Ageing"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01020-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01020-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01020-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T10:03:09Z","timestamp":1684490589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01020-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01020-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"28 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided by the IReL Consortium. This article reports on an analysis of a pooled anonymous dataset from the second round of the Irish National Audit of Dementia Care (INAD-2) audit, which was funded within the Irish National Health Service, by the Health Service Executive (HSE). There was no funding for this secondary data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no financial conflicts of interest. ST had been the Clinical Lead and Emer Begley the Acting General Manager for the HSE National Dementia Office at the time of the audit; Mairead Bracken-Scally was the National Audit Coordinator; Vida Hamilton was the National Clinical and Group Lead for acute hospitals in Ireland at the time of the audit.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Ethical approval was granted by the Clinical Research Ethics Committee (CREC) of the Cork Teaching Hospitals, University College Cork (UCC).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Source data is not available from the authors for sharing, as the primary data was collected for quality improvement purposes by the Health Service Executive and permission for sharing does not lie with the authors of this paper. The National Dementia Office can be contacted at dementia.office@hse.ie. The audit tool detailed in this study that is presented in the manuscript as Online Resource 1 is available at: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors\u2014ST, MB-S, SC, PG, VH, EB, and EOS\u2014participated in the writing and revision of this manuscript. ST, VH, EB, and PG had the idea for the article and had collected the primary dataset; ST, MB-S, SC, and EOS contributed to data analysis; MB-S wrote a preliminary partial draft and SC\/ST wrote the first full draft; all authors read and contributed to draft refinements. All authors have read and approve the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}